# Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

> clinical trial · VERIFIED · 2026-07-09

Status: RECRUITING · Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) · Condition: Recurrent Glioblastoma

- Company: National Institute of Neurological Disorders and Stroke (NINDS)
- Sector: Recurrent Glioblastoma
- Primary source: https://clinicaltrials.gov/study/NCT07416188

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.